HBOToday.com
Menu
HBOToday Editorial

Geroscience Has a New Framework for Oxygen. Its Authors Call the HBOT Evidence Preliminary.

A National Institute on Aging group has proposed 'Oxygenaging', a framework that treats the erosion of oxygen homeostasis as a driver of aging — and names hyperbaric oxygen therapy as one of three interventions worth testing. The same pages call the human HBOT biomarker evidence preliminary, while a separate precision-medicine framework proposes epigenetic clocks and warns against anti-aging claims.

longevity-antiaging evidence-review research-study fda-regulation safety-risks insurance-coverage
Stylised scientific illustration of an oxygen cascade: fine horizontal teal strata forming a luminous column across the left half of the frame, brightest toward the lower left, with one small amber-rimmed oval organelle shape at mid-left, and the right two fifths of the frame left as empty deep navy

Every so often a paper arrives that is less a discovery than a filing cabinet. It takes an idea that has been drifting around the edge of a field for years, gives it a vocabulary, an architecture and a name, and leaves the actual testing to whoever comes next. In September, Aging Cell published one of those. Seven authors, six of them at the National Institute on Aging’s intramural research program and the seventh at the University of Calgary, argued in a review titled “Oxygenaging: A Physiological Framework for Geroscience” that the body’s handling of oxygen belongs near the centre of how aging is understood. Hyperbaric oxygen therapy is in the paper, and not as a curiosity. It is one of three interventions the authors examine as a way to retune that system. Later in the same paper sits a sentence that anyone marketing a chamber as an anti-aging device should read slowly.

What the framework actually proposes

The starting point is a piece of physiology that predates the longevity business by a century. Oxygen moves from air to mitochondrion along what the authors call the oxygen cascade, and in a young organism that journey is one of the most tightly regulated processes in the body. Hypoxic stress, whether it comes from the environment or from a badly perfused tissue, switches on an adaptive programme: anabolic pathways are restrained, mitochondrial performance is optimised, cellular quality-control systems are reinforced.

Aging degrades that programme at several points at once. Angiostatic signalling rises. Endothelial metabolism becomes dysregulated. Alveolar ventilation and pulmonary gas exchange lose efficiency, in the two currencies the paper names — ventilation-perfusion matching and diffusion capacity. The consequence is microvascular rarefaction and a low-grade, persistent mismatch between oxygen delivery and oxygen demand at the level of the tissue.

The argument the authors want to make is stronger than “old tissues get less oxygen.” They propose that the gradual erosion of oxygen homeostasis is not simply a byproduct of aging but a driver of molecular damage and functional decline. The mechanisms they marshal are familiar to anyone who has read a senescence paper — mitochondrial electron leaks, amplification of oxidative stress, iron dyshomeostasis, ferroptosis, epigenetic remodelling — but the causal order is theirs, with oxygen supply at the front of it. The sentence that carries the thesis has a certain grim elegance: the aged cell, they write, is caught between hypoxic energy failure and hyperoxic iron-mediated death.

Where the chamber sits in all this

Three interventions appear under the heading of things that alter oxygen availability: intermittent hypoxia, hyperbaric oxygen therapy, and intermittent hypoxic-hyperoxic training. The review treats all three as instruments rather than supplements. Its phrase is that they should be understood not as oxygen top-ups but as molecular tools designed to retune homeostatic machinery whose efficiency and precision decline with age.

For hyperbaric therapy, the mechanism on offer is the hyperoxic-hypoxic paradox. The idea is that the rapid return to normoxia from hyperoxia is read by the cell as a relative hypoxic event, and that the size of the pressure drop — from above 1.5 ATA back to one atmosphere — sets the amplitude of the signal without ever producing genuine tissue hypoxia. The authors give hyperbaric therapy credit for something that pure hypoxia cannot do: where uncontrolled HIF-1α signalling builds chaotic, leaky, immature vessels, they write that hyperbaric oxygen drives normalised, structured angiogenesis, supplying the oxidative substrate that collagen maturation and basement-membrane stabilisation require.

The evidence they attach to that mechanism is a table row: 100 per cent oxygen at more than 2.0 ATA, sixty sessions of ninety minutes, producing telomere elongation of more than twenty per cent and a targeted reduction in senescent T cells of about thirty-seven per cent. That row is sourced to a single trial. Hachmo and colleagues, publishing in Aging in 2020, enrolled thirty-five independently living adults aged 64 and older for sixty daily exposures and reported telomere lengthening across T helper, T cytotoxic, natural killer and B cells, with the largest change in B cells at 37.63 per cent after the course, alongside a 37.30 per cent fall in senescent T helpers. That trial is the one the telomere claim rests on, and it is a thirty-five-person, single-centre study.

The caveat, and the experiment behind it

Here is the sentence. Having described the telomere findings, the authors write that evidence that hyperbaric oxygen modifies validated biomarkers of biological aging in healthy older adults “remains preliminary and requires confirmation in larger randomized controlled trials.” Elsewhere they describe the same literature as resting on “one small prospective study.”

That is not boilerplate hedging, because the same review explains why the margin is thin. Its abstract closes by observing that interventions which alter oxygen availability demonstrate adaptive potential while highlighting “the narrow margin between beneficial stress and injury.” In frail elderly populations, the authors warn, aggressive hypoxic or hyperoxic protocols could amplify oxidative stress, drive inflammation through NF-κB activation, or precipitate ferroptosis where the labile iron pool is already expanded — a convergence they name Ferroaging and explicitly decline to explore.

Then comes the detail that makes the warning concrete rather than rhetorical. The senior authors describe their own mouse experiment: female C57BL/6 animals given intermittent hypoxia at 2.5 minutes per cycle, eight hours a day, for four weeks. The result was up to five months of epigenetic age acceleration in lung, spleen and heart — and it appeared in old mice only, not in adult ones, and it reversed after four weeks back at normoxia. A parallel observation runs through the same section: chronic intermittent hypoxia of the sort produced by obstructive sleep apnoea has been shown to accelerate epigenetic aging markers in blood DNA, a change reported as potentially reversible with adherent CPAP.

Sit with that for a moment, because it cuts in two directions. The fluctuating oxygen exposure the review treats as a beneficial stress is, in a pathological version, what sleep apnoea does to people for eight hours a night. The difference between the two is dose, waveform and the age of the tissue receiving it — which is precisely the argument the review is making, and precisely the question that a chamber sold as “mild hyperbaric” cannot answer.

The measurement problem, and the people proposing to fix it

If the frameworks agree on anything, it is that nobody has been writing down the dose properly. In July, Journal of Translational Medicine carried a proposal from a Shenzhen group for treating hyperbaric oxygen as a titratable drug. Its two dose metrics are a pressure-time integral, pressure in atmospheres absolute multiplied by minutes, and a cumulative oxygen exposure that multiplies that integral by the oxygen fraction. The worked comparison in the paper is worth quoting because it dismantles the usual shorthand: a ninety-minute session at 2.0 ATA carries a nominal pressure-time integral of 180 ATA-minutes, while a sixty-minute session at 2.4 ATA carries 144 — and yet the second may generate higher peak oxidative and central-nervous-system arousal risk, because waveform amplitude and air-break structure differ. Equal pressure-time integrals, in other words, are not equal exposures.

Around that dose accounting the authors build three tiers of biomarkers. Proximal sensors cover redox balance, mitochondrial function, endothelial and microcirculatory response. Mediators cover inflammation, immunity and aging signatures. Integrative endpoints — the tier that matters for anyone selling rejuvenation — include DNA methylation clocks, named in the paper as GrimAge and PhenoAge, which the authors expect to move over eight to twelve weeks and beyond. The same paper is unusually candid about the state of its own subject. In a table of clinical contexts, the row for longevity and healthy ageing reads that mechanistic and small-study signals exist but that direct clinical outcome evidence is immature. And the clocks themselves are placed carefully: they should be considered advanced research or registry-level tools rather than routine clinical titration instruments until prospective clinical utility has been demonstrated.

The transparency does not stop there. Three of the six authors list an affiliation with Yiyuan Longevity Technology of Shenzhen, and while the paper’s declarations record no competing interests, the same statement adds that commercial or longevity-clinic applications of hyperbaric oxygen require particular caution, and that the framework should not be used to imply validated anti-aging efficacy or to support unproven commercial claims. A company with longevity in its name co-authored a paper that goes out of its way to say the framework must not be read as proof of anti-aging. That is either the most honest document in this corner of the field this year or the most carefully lawyered, and probably both.

What the human data can currently carry

A prospective study published in August went at the same question from Shenyang, in Immunity & Ageing. Chu and colleagues ran thirty sessions at 2.5 ATA with 100 per cent oxygen for sixty minutes, and measured relative telomere length and the proportions of CD28-negative, CD27-negative senescent T cells at baseline and after every ten sessions, together with plasma TNF-α, interleukin-1β and interleukin-10. Their cohort was mixed: apparently healthy volunteers alongside patients receiving hyperbaric therapy for clinical indications.

Relative telomere length rose by up to 29.0 per cent after thirty sessions, with a Cohen’s d of 0.70, and the senescent T-cell fractions fell, most clearly within the CD8-positive compartment. The three cytokines, taken across the whole cohort, did not change significantly over time. The interesting part is the subgroup analysis. Younger and middle-aged participants, women and people with a normal body-mass index showed larger reductions in senescent T cells, while middle-aged participants and men showed significant cytokine reductions after only ten sessions. Response depended on who was in the chamber.

That heterogeneity is exactly what the precision framework is designed for, and it is also why a cohort average makes a poor advertisement. What the Aging Cell review cites as human support is telomere length and senescent-cell counts. Neither is a methylation clock. An epigenetic age endpoint, prespecified and reported, is the thing the framework asks for and the thing the published human literature does not yet contain.

What no regulator has said

None of this is on a list that decides who pays. The Undersea and Hyperbaric Medical Society’s fifteenth-edition indications run from 01, air or gas embolism, to 15, avascular necrosis, and the page as it stands this week contains no entry for longevity, anti-aging, senescence or telomeres — the words do not appear on it at all. Medicare’s National Coverage Determination 20.29, effective since April 2017, limits reimbursement to fifteen named conditions, beginning with acute carbon monoxide intoxication and ending with diabetic wounds of the lower extremities that meet three criteria. Aging is not among them.

The Food and Drug Administration’s August 2025 letter to health care providers is the other document people reach for, and it should not be used this way. It reports fires involving hyperbaric devices that caused serious injuries and deaths, states that the root cause is not currently known, calls serious adverse events rare, and asks providers to maintain staff training, to keep patients properly monitored and supervised for the duration of treatment, and to follow manufacturer cleaning and maintenance intervals. It contains no list of indications at all. The absence that matters here belongs to the society and the payer, not to the device letter.

So the position at the end of 2026 is this. A group at the National Institute on Aging has given oxygen a place in geroscience and named the chamber as one of three ways to intervene in it. A separate group has proposed how such an intervention might finally be measured, and disclosed its commercial interest while doing so. The human evidence consists of small prospective studies reporting telomeres and senescent cells, and the review’s own verdict on it is the word preliminary. What would change that verdict is not another cohort with a striking percentage. It is a randomized trial with a prespecified methylation-age endpoint, a control arm matched on pressure-time integral, and a protocol that records waveform and air breaks — the three things the frameworks agree have been missing. Until then, the most reputable sentence in the field is the one the NIH authors wrote against their own enthusiasm.

Sources

  1. Donega S, Fishbein KW, Dominelli P, Herman AB, de Cabo R, Gorospe M, Ferrucci L. Oxygenaging: A Physiological Framework for Geroscience. Aging Cell 2026;25(9):e70664
  2. Simayijiang H, Lin Y, Zhong T, Li Z, Zhang K, Long Y. Precision hyperbaric oxygen therapy: a biomarker-driven framework. Journal of Translational Medicine 2026;24(1):1351
  3. Chu HT, Zhao H, Wang SS, Meng X, Wang D, Zhu XB, Wang Y, Yang XW. Hyperbaric oxygen therapy modulates immune aging in a personalized manner: a linear mixed-effects analysis. Immunity & Ageing 2026;23(1):43
  4. Hachmo Y, Hadanny A, Abu Hamed R, et al. Hyperbaric oxygen therapy increases telomere length and decreases immunosenescence in isolated blood cells: a prospective trial. Aging (Albany NY) 2020;12(22):22445-22456
  5. Undersea and Hyperbaric Medical Society. Hyperbaric Oxygen Therapy Indications, 15th Edition
  6. Centers for Medicare & Medicaid Services. National Coverage Determination 20.29, Hyperbaric Oxygen Therapy (effective 04/03/2017)
  7. U.S. Food and Drug Administration. Follow Instructions for Safe Use of Hyperbaric Oxygen Therapy Devices — Letter to Health Care Providers, 25 August 2025